Dade's Emit II plus test for Ecstasy:
This article was originally published in Clinica
Dade Behring has received US FDA 510K clearance to sell a rapid screening test for detecting Ecstasy in urine. The Emit II plus Ecstasy assay screens urine for the following illegal substances: methylenedioxymethamphetamine (MDMA, or "Ecstasy"), methylenedioxyethylamphetamine (MDEA) and methylenedioxyamphetamine (MDA). It complies with proposed SAMSHA (Substance Abuse and Mental Health Services Administration) and European regulations, and has approved applications for use on Dade's Syva 30R analyser and on systems made by Olympus. Its availability on Dade's Viva-E and V-Twin drug-testing systems is expected this month, with other open chemistry systems to follow, said the Deerfield, Illinois firm.
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.